Emergent BioSolutions Inc. (NYSE:EBS) announced on January 8 that it has received an order worth up to $21.5 million from the US Department of War. The order involves the supply of BioThrax, the company's primary product for anthrax protection, primarily for military personnel at high risk of exposure.
Deliveries are scheduled to occur throughout 2026, with a one-year base period and optional extensions into 2027 and 2028. Management noted that BioThrax remains the only FDA-approved anthrax vaccine. The order aligns with the company's ongoing role in providing vaccines for US defense needs against biological threats.
On the same day, Emergent BioSolutions also announced its collaboration with PANTHER to fund the ongoing "MpOx Study in Africa." This is an Africa CDC-led trial testing potential treatments for Mpox. Safety data from the first 50 randomized patients were collected in December, and the trial was cleared to proceed without any issues.
Management stated that this partnership positions the company in a high-demand area of Mpox preparedness amid ongoing outbreaks. Emergent BioSolutions is a life sciences company focused on providing solutions to public health threats, including opioid overdoses, infectious diseases, and biological threats.